rhGH therapy does not impact lifetime IGF-1 exposure in SGA children
Years of treatment with recombinant human growth hormone does not increase the cumulative lifetime exposure to insulin-like growth factor-1 above the population average in children born small for gestational age, a study shows.
PEGylated weekly rhGH promising in idiopathic short stature
A weekly injectable PEGylated recombinant human growth hormone gives significantly better height outcomes than no treatment in children with idiopathic short stature, shows a phase 2 trial.
At least 2 years of growth checks after SGA birth ‘mandatory’ to identify short stature risk
Small-for-gestational age children should undergo regular measurements for the first 2 years after birth to help identify individuals who will benefit from recombinant human growth hormone therapy, German researchers advise.
No long-term cardiometabolic consequences of childhood rhGH therapy in adults born SGA
Cardiometabolic risk in people born small for gestational age more than a decade after finishing therapy with recombinant human growth hormone is no higher than in those never given the treatment, a study shows.
Somatropin safety and efficacy confirmed for childhood growth disorders
Analysis of real-world data indicates that the recombinant human growth hormone somatropin is well tolerated and effective for children with a range of growth hormone disorders and other conditions associated with short stature.
Brain imaging ‘provides valuable information’ in girls with central precocious puberty
More than half of girls with central precocious puberty have abnormal findings on magnetic resonance imaging of the brain, report researchers.
Model predicts infant BMI trajectory to obesity
A small number of clinical predictors and blood metabolites at birth may accurately predict which infants will have a BMI trajectory leading to overweight or obesity, a study suggests.
Androgen increases may compensate for low birthweight in infant boys
A study of preterm boys shows increased androgen levels at the estimated time of birth in those with low birthweight.
Young people largely remain committed to endocrine transgender treatment
Most young people treated within a paediatric gender identity development service remain committed to pursuing hormonal treatment in line with their perceived gender, research shows.
Most young transgender people continue to identify as gender variant into adulthood
Most children and adolescents who identify as transgender or gender variant continue with hormone interventions after discharge from youth endocrine services, a study shows.
